• Molecular NameMelatonin
  • SynonymMEL; MLT; N-acetyl-5-methoxytryptamine; Pineal Hormone
  • Weight232.283
  • Drugbank_IDDB01065
  • ACS_NO73-31-4
  • Show 2D model
  • LogP (experiment)1.536
  • LogP (predicted, AB/LogP v2.0)2.23
  • pkaN/A
  • LogD (pH=7, predicted)2.23
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.73
  • LogSw (predicted, AB/LogsW2.0)0.13
  • Sw (mg/ml) (predicted, ACD/Labs)4.15
  • No.of HBond Donors1
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds4
  • TPSA50.69
  • StatusFDA approved
  • Administration In humans: orally, as capsules, tablets or liquid, sublingually, or as transdermal patches. In lab animals: also injection.
  • PharmacologyMelatonin has been studied for the treatment of cancer, immune disorders, cardiovascular diseases, depression, seasonal affective disorder (SAD), circadian rhythm sleep disorders and sexual dysfunction.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability12.0
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic via CYP1A2 mediated 6-hydroxylation
  • Half life35~50 min
  • ExcretionUrine
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A